Press Release
Astellas Announces Personnel Changes and
Organizational Changes
Tokyo, February 5, 2018 - Astellas Pharma Inc. (President and CEO: Yoshihiko Hatanaka) today announced the personnel changes and organizational changes as below.
1. Appointments of Senior Corporate Executive effective April 1, 2018
Name | New Title | Current Title |
Chihiro Yokota | CEO's Office | Head of Japan-Asia Development, Development |
Wataru Uchida | CEO's Office | Head of Drug Discovery Research |
Makoto Takeuchi | CEO's Office | Senior Vice President, External Relations |
CEO: Chief Executive Officer
2. Appointments of Corporate Executive effective April 1, 2018
Name | New Title | Current Title |
Kazunori Okimura | CEO's Office | Corporate Vice President, Legal |
Katsumi Ozawa | CEO's Office | General Manager, Tokyo Branch, Japan Sales & Marketing |
Chikashi Takeda | CFO and Head of Finance | CFO |
Fumiaki Sakurai | CAO & CECO and Head of Human Resources | CAO & CECO |
Naoki Okamura | CSTO | Corporate Vice President, Corporate Planning |
Akihiko Iwai | Head of Drug Discovery Research | Divisional Senior Vice President, Candidate Discovery Science Labs., Drug Discovery Research |
Shigeki Tanaka | Head of Japan-Asia Development, Development | Vice President, Japan-Asia Clinical Development 1, Development |
Atsushi Kamide | Vice President, External Relations | Vice President, Healthcare Policy & CSR |
CFO: Chief Finance Officer
CAO: Chief Administrative Officer CECO: Chief Ethics & Compliance Officer CSTO: Chief Strategy Officer
1
3. Resignation of Senior Corporate Executive effective June 15, 2018
Name | Title (effective on April 1, 2018) |
Chihiro Yokota | CEO's Office |
Wataru Uchida | CEO's Office |
Makoto Takeuchi | CEO's Office |
4. Resignation of Corporate Executive effective June 15, 2018
Name | Title (effective on April 1, 2018) |
Kazunori Okimura | CEO's Office |
Katsumi Ozawa | CEO's Office |
5. Appointment of Senior Corporate Executive effective June 15, 2018
Name | Title (effective on April 1, 2018) |
Chikashi Takeda | CFO and Head of Finance |
Nobuaki Tanaka | Head of Japan Sales & Marketing |
Akihiko Iwai | Head of Drug Discovery Research |
Atsushi Kamide | Senior Vice President, External Relations |
6. New Corporate Executives effective June 15, 2018
Name | Title (effective on April 1, 2018) |
Shiro Yamamoto | General Manager, Tokyo Branch, Japan Sales & Marketing |
Masaaki Hirano | Corporate Vice President, Corporate Planning |
Yoshitsugu Shitaka | President, Astellas Institute for Regenerative Medicine |
7. Personnel Changes effective April 1, 2018
Name | New Title | Current Title |
Kazuhiko Kawasaki | Head of Internal Auditing and Vice President, Internal Auditing | Vice President, Internal Auditing |
Masaaki Hirano | Corporate Vice President, Corporate Planning | Divisional Senior Vice President, Modality Research Labs., DDR |
Yuta Watanabe | Vice President, Rx+ Business Accelerator | Vice President, Japan-Asia Planning & Administration, Medical & Development |
Osamu Chihara | Vice President, Healthcare Policy & CSR | Senior Director, Healthcare Policy & CSR |
Stig Ogata | Vice President, Corporate Communications | Senior Director, Business Strategy & Operations, Marketing Strategy Astellas Pharma US, Inc. |
Satoshi Nozaki
Vice President, Legal
Staff Executive Director, Legal
Minori Saitoh
Vice President, Research Planning & Administration, DDR
Vice President, Drug Repurposing and Application
Management, DDR
Taro Masunaga
Vice President, Research Portfolio Planning, DDR
Executive Director, Innovation &
Incubation Research Labs.,
DDR
Tatsuaki Morokata
Divisional Senior Vice President,
Innovation & Incubation Research Labs., DDR
Executive Director, Product &
Portfolio Strategy
Yuichi Tomura
Divisional Senior Vice President,
Candidate Discovery Science
Labs., DDR
Vice President, Research Portfolio Planning, DDR
Shigeki Kawabata
Vice President, New Medical
Solutions, DDR
Vice President, Evolving Medical Solutions, DDR
Noriyuki Masuda
Divisional Senior Vice President, Modality Research Labs., DDR
Vice President, Research Planning & Administration, DDR
Shigeru Nakaji
Vice President, Japan-Asia Planning & Administration, Medical & Development
Executive Director, Japan-Asia
Clinical Development 1,
Development
Hiroaki Ishikura
Vice President, Japan-Asia
Clinical Development 1,
Development
Senior Director, Japan-Asia
Clinical Development 1,
Development
Kei Motonaga
Vice President, Analytical
Research Laboratories, Pharmaceutical Technology
Senior Director, Quality Control
Division, Yaizu Technology
Center
Koji Nagao
Vice President, Pharmaceutical Science & Technology Labs., Pharmaceutical Technology
Pharmaceutical Technology
Masaaki Usui
Divisional Senior Vice President,
Product Marketing, Japan Sales & Marketing
Vice President, Corporate
Communications
Shiro Yamamoto
General Manager, Tokyo Branch, Japan Sales &
Marketing
Divisional Senior Vice President,
Product Marketing, Japan Sales & Marketing
Takashi Matsuki
Vice President, Business Planning, Asia & Oceania
Business
President, P.T. Astellas Pharma
Indonesia
DDR: Drug Discovery Research
[Staff Executive Director]
Name | New Title | Current Title |
Masahiro Takeuchi | Staff Executive Director, DDR | Executive Director, Candidate Discovery Science Labs., DDR |
Tomoyuki Yasunaga | Staff Executive Director, Planning & Administration, DDR | Executive Director, Planning & Administration, DDR |
Hideto Yamaguchi | Staff Executive Director, Pharmaceutical Technologies | Senior Director, Pharmaceutical Technologies |
8. Organizational Changes effective April 1, 2018
Establishment of Rx+ Business Accelerator
To create new business models for Rx+ (innovative medical solutions by combining a variety of internal and external capabilities) and build business case capability, implement idea-seeking collaborations and create processes to manage Rx+ projects, a special team within Corporate Planning will be reorganized into the Rx+ Business Accelerator.
Changes to Drug Discovery Research
To ensure reliability and increase the efficiency of research program management, the application management function of Drug Repurposing will be transferred to Research Program Management. The drug repurposing research function of Drug Repurposing will be in transferred to EMed, and Drug Repurposing will be effectively dissolved. EMed will be transferred to New Medical Solutions, and serve as a research function, including drug repurposing research of new medical solutions.
Establishment of Pharmaceutical Science & Technology Labs
To shorten the time from discovery to Proof-of-Concept (POC), a part of functions / staff at the current four Labs (Process Chemistry Labs, Biotechnology Labs, Pharmaceutical Research & Technology Labs and Analytical Science Labs) in Pharmaceutical Technologies will be transferred / integrated into Pharmaceutical Science & Technology Labs (PSTL). The PSTL will have flexibility to respond to every modality within the five Labs. structure of Pharmaceutical Technologies.
###
About Astellas
Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We focus on Urology, Oncology, Immunology, Nephrology and Neuroscience as prioritized therapeutic areas while advancing new therapeutic areas and discovery research leveraging new technologies/modalities. We are also creating new value by combining internal capabilities and external expertise in the medical/healthcare business. Astellas is on the forefront of healthcare change to turn innovative science into value for patients. For more information, please visit our website atwww.astellas.com/en.
Information about pharmaceutical products (including products currently in development) which is included in this press release is not intended to constitute an advertisement or medical advice.
Contacts for inquiries or additional information:
Astellas Pharma Inc.
Corporate Communications
TEL: +81-3-3244-3201 FAX: +81-3-5201-7473
Astellas Pharma Inc. published this content on 05 February 2018 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 05 February 2018 05:09:01 UTC.
Original documenthttps://www.astellas.com/en/corporate/news/pdf/180205_2_Eg.pdf
Public permalinkhttp://www.publicnow.com/view/D45194D30671C09A19D082C552789B4A8811DCD6